Is UroGen Pharma Stock a Good Investment?
UroGen Pharma Investment Advice | URGN |
- Examine UroGen Pharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research UroGen Pharma's leadership team and their track record. Good management can help UroGen Pharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact UroGen Pharma's business and its evolving consumer preferences.
- Compare UroGen Pharma's performance and market position to its competitors. Analyze how UroGen Pharma is positioned in terms of product offerings, innovation, and market share.
- Check if UroGen Pharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about UroGen Pharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in UroGen Pharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if UroGen Pharma is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine UroGen Pharma Stock
Researching UroGen Pharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 89.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 239.57. UroGen Pharma recorded a loss per share of 3.02. The entity had not issued any dividends in recent years.
To determine if UroGen Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding UroGen Pharma's research are outlined below:
| UroGen Pharma generated a negative expected return over the last 90 days | |
| UroGen Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 82.71 M. Net Loss for the year was (102.24 M) with profit before overhead, payroll, taxes, and interest of 56.7 M. | |
| UroGen Pharma currently holds about 111.74 M in cash with (76.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.91. | |
| UroGen Pharma has a poor financial position based on the latest SEC disclosures | |
| Over 89.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from gurufocus.com: RA Capital Management, L.P. Increases Stake in UroGen Pharma Ltd |
UroGen Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in UroGen Pharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to UroGen Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact UroGen Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises UroGen Pharma's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-11-14 | 2017-09-30 | -0.05 | -0.02 | 0.03 | 60 | ||
2024-05-13 | 2024-03-31 | -0.87 | -0.97 | -0.1 | 11 | ||
2018-03-15 | 2017-12-31 | -0.62 | -0.74 | -0.12 | 19 | ||
2017-08-14 | 2017-06-30 | -0.57 | -0.7 | -0.13 | 22 | ||
2019-08-09 | 2019-06-30 | -1.22 | -1.08 | 0.14 | 11 | ||
2023-03-16 | 2022-12-31 | -1.07 | -1.22 | -0.15 | 14 | ||
2018-05-15 | 2018-03-31 | -0.72 | -0.88 | -0.16 | 22 | ||
2023-11-14 | 2023-09-30 | -0.85 | -0.68 | 0.17 | 20 |
UroGen Pharma's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 535.93 M.Market Cap |
|
UroGen Pharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.57) | (0.60) | |
| Return On Capital Employed | (0.45) | (0.47) | |
| Return On Assets | (0.57) | (0.60) | |
| Return On Equity | 1.57 | 1.65 |
Determining UroGen Pharma's profitability involves analyzing its financial statements and using various financial metrics to determine if UroGen Pharma is a good buy. For example, gross profit margin measures UroGen Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of UroGen Pharma's profitability and make more informed investment decisions.
Evaluate UroGen Pharma's management efficiency
UroGen Pharma has return on total asset (ROA) of (0.2112) % which means that it has lost $0.2112 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (14.8126) %, meaning that it created substantial loss on money invested by shareholders. UroGen Pharma's management efficiency ratios could be used to measure how well UroGen Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of December 2024, Return On Equity is likely to grow to 1.65, while Return On Tangible Assets are likely to drop (0.60). At this time, UroGen Pharma's Other Current Assets are very stable compared to the past year. As of the 1st of December 2024, Non Currrent Assets Other is likely to grow to about 2.4 M, while Total Assets are likely to drop about 98.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.26) | (2.15) | |
| Tangible Book Value Per Share | (2.26) | (2.15) | |
| Enterprise Value Over EBITDA | (6.86) | (6.51) | |
| Price Book Value Ratio | (6.63) | (6.30) | |
| Enterprise Value Multiple | (6.86) | (6.51) | |
| Price Fair Value | (6.63) | (6.30) | |
| Enterprise Value | 221.4 M | 197.9 M |
At UroGen Pharma, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Beta 1.126 |
Basic technical analysis of UroGen Stock
As of the 1st of December, UroGen Pharma has the Coefficient Of Variation of (2,583), variance of 8.61, and Risk Adjusted Performance of (0.02). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of UroGen Pharma, as well as the relationship between them.UroGen Pharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific UroGen Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on UroGen Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases UroGen Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
UroGen Pharma's Outstanding Corporate Bonds
UroGen Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. UroGen Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most UroGen bonds can be classified according to their maturity, which is the date when UroGen Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Understand UroGen Pharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing UroGen Pharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.08) | |||
| Mean Deviation | 2.17 | |||
| Coefficient Of Variation | (2,583) | |||
| Standard Deviation | 2.93 | |||
| Variance | 8.61 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.30) | |||
| Total Risk Alpha | (0.61) | |||
| Treynor Ratio | (0.09) | |||
| Maximum Drawdown | 15.03 | |||
| Value At Risk | (5.50) | |||
| Potential Upside | 5.56 | |||
| Skewness | (0.14) | |||
| Kurtosis | 0.9766 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.08) | |||
| Mean Deviation | 2.17 | |||
| Coefficient Of Variation | (2,583) | |||
| Standard Deviation | 2.93 | |||
| Variance | 8.61 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.30) | |||
| Total Risk Alpha | (0.61) | |||
| Treynor Ratio | (0.09) | |||
| Maximum Drawdown | 15.03 | |||
| Value At Risk | (5.50) | |||
| Potential Upside | 5.56 | |||
| Skewness | (0.14) | |||
| Kurtosis | 0.9766 |
Consider UroGen Pharma's intraday indicators
UroGen Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of UroGen Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
UroGen Pharma Corporate Filings
F3 | 18th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 12th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
UroGen Stock media impact
Far too much social signal, news, headlines, and media speculation about UroGen Pharma that are available to investors today. That information is available publicly through UroGen media outlets and privately through word of mouth or via UroGen internal channels. However, regardless of the origin, that massive amount of UroGen data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of UroGen Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of UroGen Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to UroGen Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive UroGen Pharma alpha.
UroGen Pharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards UroGen Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
UroGen Pharma Corporate Management
| Dong Kim | Chief Officer | Profile | |
| Jason JD | Chief Counsel | Profile | |
| Sari PrutchiSagiv | Marketing Director | Profile | |
| Jason Smith | Chief Counsel | Profile | |
| Bryon Wornson | Advocacy Talent | Profile | |
| Eric Zanten | Director Communications | Profile | |
| Christopher CPA | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share 2.389 | Quarterly Revenue Growth 0.209 | Return On Assets (0.21) | Return On Equity (14.81) |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between UroGen Pharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.